Meplazumab for Injection + Sterile normal saline (0.9%)

Phase 1Withdrawn

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Malaria (Plasmodium Falciparum)

Conditions

Malaria (Plasmodium Falciparum)

Trial Timeline

Mar 1, 2023 → Mar 1, 2024

NCT ID

NCT04327310

About Meplazumab for Injection + Sterile normal saline (0.9%)

Meplazumab for Injection + Sterile normal saline (0.9%) is a phase 1 stage product being developed by Pacific Biosciences for Malaria (Plasmodium Falciparum). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04327310. Target conditions include Malaria (Plasmodium Falciparum).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04327310	Phase 1	Withdrawn	Mar 1, 2023	Mar 1, 2024	Malaria (Plasmodium Falciparum)
NCT05113784	Phase 2/3	Completed	Jan 21, 2022	Oct 8, 2022	Covid19
NCT04586153	Phase 2/3	Completed	Feb 15, 2021	Dec 18, 2022	COVID-19

Competing Products

20 competing products in Malaria (Plasmodium Falciparum)

See all competitors

Product	Company	Stage	Hype Score
SAR97276A	Sanofi	Phase 2	51
SJ733 + Cobicistat	Eisai	Phase 1	33
(+)-SJ000557733 (SJ733)	Eisai	Phase 2	52
E1018 + Placebo	Eisai	Phase 1	33
ZY19489 + Ferroquine (FQ) + Placebo	Zydus Lifesciences	Phase 1	33
ZY19489 Capsule + Placebo Capsule	Zydus Lifesciences	Phase 1	33
M5717 330 mg + M5717 500 mg + M5717 660 mg + Pyronaridine 360 mg + Pyronaridine 360 mg + Pyronaridine 540 mg + Pyronaridine 720 mg	Merck	Phase 2	52
MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanil	Merck	Phase 1	33
M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mg	Merck	Phase 2	52
KLU156 + Coartem	Novartis	Phase 3	77
KAF156	Novartis	Phase 2	52
KAE609 + IV Artesunate + Coartem	Novartis	Phase 2	52
KAE609	Novartis	Phase 2	52
artemether:lumefantrine (2.5 mg:30 mg)	Novartis	Phase 2/3	65
Artemether-lumefantrine (COA566)	Novartis	Phase 2/3	65
INE963	Novartis	Phase 2	52
Ganaplacide + Itraconazole	Novartis	Phase 1	33
KAE609 + Piperaquine Phosphate	Novartis	Phase 1	33
Artemether-lumefantrine	Novartis	Phase 3	77
KAE609 + SoC (Coartem) + KLU156	Novartis	Phase 2	52

Other Products from Pacific Biosciences

pantoprazole + bismuth + metronidazole + tetracyclineApproved

EmtricitabineApproved

A single oral 5 mg of duterium labeled methamphetamineApproved

RamiprilApproved

Emtricitabine plus adefovir dipivoxilApproved